RxDoctor Payments DataLook up a doctor →

Vinay Malhotra, MD

Cardiovascular Disease · Tacoma, WANPI 1144204355

Payments from drug & device makers

$4,992,311in general payments, 2019–2025

Across 192 payments — averaging $26,002 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1.4M
  • Eli Lilly$1M
  • Novartis$952K
  • Amgen$790K
  • GSK$428K
  • Genentech, Inc.$143K
  • plus $232K from 12 others

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,992,311 in reported general payments places this provider in the 95th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$567,778
Medicare patients
2,337
Services billed
5,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →